Less than a year after emerging from stealth, Tome Biosciences Inc. now plans to eliminate all the jobs at its Watertown facility — including the positions of its chief executive and chief scientific officers.
Tome debuted in December 2023 with quite the haul in venture capital funding: $213 million across Series A and B investment rounds. The company counted about 140 employees, at the end of last year, nearly all of whom were based at its labs in Watertown.
Stream NBC10 Boston news for free, 24/7, wherever you are.
WATCH HEREMore on this story from Boston Business Journal
Get updates on what's happening in Boston to your inbox with our News Headlines newsletter.
SIGN UP Copyright Boston Business Journal
